Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

Capricor Therapeutics, Inc. ( (CAPR) ) has released its Q3 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc.

Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Ted Tent ...

Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is ...

Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago. These ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Capricor Therapeutics Inc. (CAPR) on Wednesday reported a loss of $12.6 million in its third quarter. The San Diego-based company said it had a loss of 38 cents per ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Shares of Capricor Therapeutics fell more than 10% in premarket trading Thursday after the biotechnology company said it is raising about $75 million in a public stock offering. The San Diego ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...